William Blair Upgrades Genmab A/S (NASDAQ:GMAB) to Outperform

Genmab A/S (NASDAQ:GMAB) was upgraded by stock analysts at William Blair from a “market perform” rating to an “outperform” rating in a research note issued to investors on Tuesday, MarketBeat reports.

GMAB has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average target price of $42.17.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $21.98 on Tuesday. The company has a market capitalization of $14.55 billion, a P/E ratio of 12.63, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company’s 50-day moving average is $21.30 and its 200 day moving average is $22.59. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its stake in Genmab A/S by 94.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares during the period. AIMZ Investment Advisors LLC bought a new position in Genmab A/S during the fourth quarter valued at $3,525,000. HighTower Advisors LLC bought a new position in shares of Genmab A/S during the third quarter valued at approximately $273,000. Verition Fund Management LLC bought a new position in shares of Genmab A/S in the third quarter worth about $709,000. Finally, FMR LLC grew its stake in Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after acquiring an additional 33,076 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.